Auxilium receives notification of Xiaflex PDUFA extension Auxilium Pharmaceuticals announced that the FDA has notified the company that it is extending the Prescription Drug User Fee Act, or PDUFA, goal date for the company's supplemental biologics license application for XIAFLEX for the treatment of Peyronie's disease from September 6 to December 6.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.
Auxilium Xiaflex likely to be approved, says Stifel Stifel thinks there is at least an 80% chance that Auxilium's Xiaflex for Peyronie’s disease will be approved by the FDA. Noting that the drug has a December 6 PDUFA date, Stifel believes the stock can "trade well into the mid-$20s" if the drug is approved. The firm keeps a Buy rating on the stock.